SG Americas Securities LLC Reduces Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

SG Americas Securities LLC reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 83.7% during the first quarter, Holdings Channel reports. The firm owned 20,649 shares of the biotechnology company’s stock after selling 106,036 shares during the quarter. SG Americas Securities LLC’s holdings in BioCryst Pharmaceuticals were worth $197,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of BCRX. Larson Financial Group LLC lifted its holdings in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after buying an additional 3,267 shares during the period. Focus Partners Wealth bought a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. grew its stake in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the period. Envestnet Portfolio Solutions Inc. bought a new position in BioCryst Pharmaceuticals in the fourth quarter worth $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at $81,000. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of analyst reports. Needham & Company LLC decreased their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Wedbush reduced their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Cantor Fitzgerald upped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th. Finally, HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.78.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded down $0.27 during trading hours on Friday, reaching $10.45. The company had a trading volume of 3,359,241 shares, compared to its average volume of 6,231,274. The business has a fifty day moving average price of $9.14 and a 200-day moving average price of $8.44. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22. The firm has a market cap of $2.66 billion, a PE ratio of -5.87 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. During the same quarter last year, the company earned $0.20 EPS. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.61 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.